Analysis of seroprevalence from blood donors, laboratories, and health checkups indicates notable age group variations.
We compared severe acute respiratory syndrome coronavirus 2 nucleocapsid antibody seroprevalence using 3 types of residual blood samples simultaneously collected in November-December 2023 from blood donors, commercial laboratories, and health checkups. Overall seroprevalence ranged from 53.5% to 58.8%, and notable variations were observed among the 30-39 and 50-59 age groups, highlighting the importance of multisource seroepidemiological surveillance.
No takes yet. Share an insight, caveat, or question.
Nishigaki et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: